Hepatic-Metabolite-Based Intermittent Fasting Enables a Sustained Reduction in Insulin Resistance in Type 2 Diabetes and Metabolic Syndrome
Horm Metab Res DOI: 10.1055/a-1510-8896Insulin resistance is the hallmark of Type 2 Diabetes and is still an unmet
medical need. Insulin resistance lies at the crossroads of non-alcoholic fatty
liver disease, obesity, weight loss and exercise resistance, heart disease,
stroke, depression, and brain health. Insulin resistance is purely nutrition
related, with a typical molecular disease food intake pattern. The insulin
resistant state is accessible by TyG as the appropriate surrogate marker, which
is found to lead the personalized molecular hepatic nutrition system for highly
efficient insulin resistance remission. Treating insulin resistance with a
molecular nutrition-centered approach shifts the treatment paradigm of Type 2
Diabetes from management to cure. This allows remission within five months, with
a high efficiency rate of 85%. With molecular intermittent fasting a
very efficient treatment for prediabetes and metabolic syndrome is possible,
improving the non-alcoholic fatty liver disease (NAFL) state and enabling the
body to lose weight in a sustainable manner. [...] Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, GermanyArticle in Thieme eJournals: Table of contents | Abstract | open access Full text
Source: Hormone and Metabolic Research - Category: Endocrinology Authors: Rohner, Markus Heiz, Robert Feldhaus, Simon Bornstein, Stefan R. Tags: Endocrine Care Source Type: research
More News: Alcoholism | Brain | Cardiology | Depression | Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Fatty Liver Disease (FLD) | Heart | Heart Disease | Hormones | Insulin | Liver | Liver Disease | Metabolic Syndrome | Neurology | Non-alcoholic Fatty Liver Diseases (NAFLD) | Nutrition | Obesity | Sports Medicine | Stroke | Urology & Nephrology | Weight Loss